Novamind Discusses Partnership with Merck for New Treatment-Resistant Depression Trial
Last week Novamind announced that its wholly-owned subsidiary, Cedar Clinical Research has been selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co., a world-leading pharmaceutical company.
The phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder.
Yaron Conforti, CEO and Director of Novamind said: “Under Dr. Robison’s leadership, Cedar Clinical Research has proven itself as a best-in-class research site for emerging mental health therapeutics. We’re excited to work with Merck, a world-class pharmaceutical company, to advance research for innovative mental health treatments.”
Sit back, relax and watch this powerful interview with Yaron Conforti, CEO and Director of Novamind.